Fresenius stock
Price history
+11.42% over the period1 year: from €48.85 (November 17, 2025) to €54.43 (November 16, 2026), +11.42%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €54.43 |
| October 30, 2026 | €47.79 |
| September 30, 2026 | €44.75 |
| August 31, 2026 | €45.24 |
| July 31, 2026 | €44.52 |
| June 30, 2026 | €39.97 |
| May 29, 2026 | €36.27 |
| April 30, 2026 | €41.25 |
| March 31, 2026 | €44.32 |
| February 27, 2026 | €50.90 |
| January 30, 2026 | €47.21 |
| December 30, 2025 | €48.98 |
| November 28, 2025 | €47.33 |
| November 17, 2025 | €48.85 |
At a glance
The company
Healthcare company providing products and services for chronically ill patients through pharmaceutical, clinical nutrition, medical technology and hospital operations
Latest results
Quarter to September 30, 2026 · EPS €0.86 (estimate €0.79)
TickerLandia's take on Fresenius
- Pricier than usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 14 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 19 vs 21 (−9%) in a group of 10.
- Strong point: Market momentum (79/100 in its group). Weak point: Profitability (25/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
+0.15% from the 52-week high
Analysts · 14 analysts
Average target€57.73+6.06% vs. price
Buy 13 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Fresenius
Compared with similar companies: strong momentum, low profitability, and low earnings stability.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow40
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 13.7 36 P/E (trailing 12 months) 19.0 47 EV/EBITDA 13.1 55 Price/book 1.47 21 Price/sales 1.28 39 Profitabilitylow25
How much it earns on revenue and capital.
Metric Value Position in group ROE 8.3% 24 ROA 3.5% 13 Gross margin 26.0% 24 Net margin 6.6% 34 Operating margin 9.9% 29 Earnings stabilitylow26
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 45 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 8 Growthlow38
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +5.90% 45 Average revenue growth (3 years) +2.03% 13 Earnings growth (year over year) +6.50% 55 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 5.16 39 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.38 34 Current ratio 1.52 82 Debt/equitycounts in reverse: lower means more financial strength 0.57 71 Dividendaverage40
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 2 years 8 Dividend yield 2.0% 62 Payout ratio 37.2% 50 Market momentumstrong79
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +20.97% 90 Relative strength (3 months) +12.60% 85 Relative strength (6 months) +26.22% 91 1-year return +9.36% 48 Riskaverage51
How much the price swings.
Metric Value Position in group Volatility (60 days) 25.1% 41 Maximum drawdown (12 months) 32.0% 73 Beta (1 year) 0.60 38
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Fresenius is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Fresenius's P/E today is 20.0, above the median of its last 10 fiscal years (13.5; between 10.8 and 26.2 from 2016 to 2025). Fresenius's P/E (trailing 12 months): 19.0, −9% against the median of a group of 10 similar companies (20.8).
Compared with 10 similar companies
| Metric | Fresenius | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 19.0 | Middle | |
| Forward P/E | 13.7 | Middle | |
| Operating margin | 9.9% | Middle | |
| ROE | 8.3% | Low | |
| Debt/equity | 0.57 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fresenius. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€5.95B
Latest quarter · Q2 2026
Net income
€382M
Latest quarter · Q2 2026
Quarterly net margin
6.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €30.2B
- P/E
- 19.0
- EPS
- €2.82
- Volume
- 826.59K
- Daily trading
- €48.29M
- Dividend yield
- 1.93%
- Last ex-dividend on May 25, 2026
How Fresenius is changing
All resultsRevenue fell 8.8% a year on average over the last 5 years
Operating margin rose from 8.5% to 10.0%
Profitable in 4 of 5 fiscal years
Returns
Fresenius returns with dividends
€1,000 invested in Fresenius 5 years ago, on November 16, 2021, would be worth €1,619 today with dividends reinvested: +61.93% in total, +10.12% per year. On price alone it would be €1,450 (+44.99%).
| Period | Fresenius | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | +20.75% | +5.90% | €1,208 |
| 6 months | +40.28% | +11.69% | €1,403 |
| Year to date | +11.13% | +9.23% | €1,111 |
| 1 year | +14.47% | +13.39% | €1,145 |
| 3 years | +113.80% | +69.45% | €2,138 |
| 5 years | +61.93% | +64.64% | €1,619 |
| 10 years | −2.08% | +150.85% | €979 |
Over the last 6 months it has done better than 65% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Fresenius: technical analysis
Fresenius is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 31.5% below its all-time closing high (€79.50, June 19, 2017).
- Trend
- Upward
- RSI (14 sessions)
- 82
- Above 70: a strong rise in a short time
- vs 200-session average
- +22.73%
Active signals
New 52-week high.
Close above the high of the previous 55 sessions.
RSI above 70: the stock has risen a lot in a short time.
since November 2, 2026
Support and resistance
Price areas where Fresenius has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€54.43
- Support€49.31−9.40%2 touches, last on January 27, 2026
- Support€48.23−11.39%2 touches, last on August 14, 2026
- Support€47.38−12.95%2 touches, last on September 28, 2026
Volatility and risk
Over the last year it has moved less than the DAX.
- Beta (1 year) vs DAX
- 0.60
- Volatility (60 sessions, annualised)
- 25.0%
- Largest fall in the last year
- −31.98%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Fresenius: seasonality
Average monthly price change over 28 years
Over the last 28 years, the strongest month for Fresenius has been November: +3.92% on average, positive in 20 years out of 27. The weakest has been September: −0.60% on average, positive in 13 years out of 28.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.67% | +1.96% | 17 of 28 |
| February | +1.02% | +0.45% | 15 of 28 |
| March | +0.82% | +1.24% | 17 of 28 |
| April | +1.24% | +1.42% | 16 of 28 |
| May | +1.33% | +3.14% | 17 of 28 |
| June | −0.51% | −0.42% | 12 of 28 |
| July | +0.66% | +0.46% | 15 of 28 |
| August | +0.29% | −0.47% | 12 of 28 |
| September | −0.60% | −0.26% | 13 of 28 |
| October | +1.27% | +0.79% | 15 of 28 |
| November | +3.92% | +4.10% | 20 of 27 |
| December | −0.43% | +0.14% | 14 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Fresenius and its competitors
Hospitals, clinics, physicians and patients with chronic or critical illnesses in North America, Europe, Asia-Pacific, Latin America and Africa are the customers of Fresenius SE & Co. KGaA. Its Fresenius Kabi unit supplies biopharmaceuticals, clinical nutrition, biosimilars, generic injectable drugs, IV fluids, infusion pumps, apheresis machines and cell therapy devices. The Fresenius Helios unit runs hospitals, medical care centers, occupational health and outpatient centers and provides medical diagnostics.
- Headquarters
- Bad Homburg vor der Höhe, Germany
- Employees
- 179,493
- Founded
- 1912
- Chief executive
- Michael Sen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| FreseniusFRE | $33.38B | 9.9% | 19.0 | +40.28% |
| Fresenius Medical CareFME | $11.84B | 10.3% | 12.1 | +8.17% |
| MedicoverMCOV.B | $3.95B | 7.4% | 39.0 | +31.17% |
| Spire Healthcare GroupSPI | $1.31B | 6.2% | — | +8.87% |
| TerveystaloTTALO | $859.12M | 8.9% | 13.6 | −21.78% |
| Tenet HealthcareTHC | $22.76B | 19.1% | 8.37 | +46.04% |
Same industry or related industries, similar size. Compare Fresenius with its competitors · Full profile
